US Bancorp DE Sells 257,458 Shares of Pfizer Inc. (NYSE:PFE)

US Bancorp DE lowered its position in Pfizer Inc. (NYSE:PFE) by 3.9% in the third quarter, Holdings Channel.com reports. The institutional investor owned 6,268,172 shares of the biopharmaceutical company’s stock after selling 257,458 shares during the period. US Bancorp DE’s holdings in Pfizer were worth $181,401,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in PFE. Bank Hapoalim BM lifted its holdings in shares of Pfizer by 2.3% during the 3rd quarter. Bank Hapoalim BM now owns 130,218 shares of the biopharmaceutical company’s stock valued at $3,769,000 after purchasing an additional 2,901 shares in the last quarter. Catalyst Financial Partners LLC lifted its stake in Pfizer by 22.5% in the third quarter. Catalyst Financial Partners LLC now owns 21,817 shares of the biopharmaceutical company’s stock valued at $631,000 after buying an additional 4,001 shares in the last quarter. Financial Advocates Investment Management boosted its holdings in shares of Pfizer by 5.5% in the third quarter. Financial Advocates Investment Management now owns 44,909 shares of the biopharmaceutical company’s stock valued at $1,300,000 after buying an additional 2,361 shares during the period. Hudson Valley Investment Advisors Inc. ADV increased its position in shares of Pfizer by 32.4% during the third quarter. Hudson Valley Investment Advisors Inc. ADV now owns 177,214 shares of the biopharmaceutical company’s stock worth $5,129,000 after acquiring an additional 43,358 shares in the last quarter. Finally, SteelPeak Wealth LLC raised its holdings in shares of Pfizer by 237.0% during the third quarter. SteelPeak Wealth LLC now owns 173,317 shares of the biopharmaceutical company’s stock worth $5,016,000 after acquiring an additional 121,889 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock traded down $0.07 during trading on Thursday, reaching $28.45. 7,098,344 shares of the company’s stock were exchanged, compared to its average volume of 37,070,223. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The firm’s fifty day moving average price is $29.06 and its 200-day moving average price is $28.56. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $161.22 billion, a PE ratio of 38.38, a PEG ratio of 0.99 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period in the prior year, the firm earned ($0.17) earnings per share. The company’s revenue was up 31.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.91%. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Analysts Set New Price Targets

PFE has been the topic of several recent research reports. Barclays lifted their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. Finally, Sanford C. Bernstein started coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.